Evidence map›Paper›PMID 36055987›Full record

ArticleBlood cancer journal2022

R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma.

Diana Al-Sarayfi, Frederik O Meeuwes, Müjde Durmaz, Djamila E Issa, Rolf E Brouwer, Aart Beeker, Anna van Rhenen, Pim G N J Mutsaers, Lara H Böhmer, Marjolein W M van der Poel and 6 more

Open access · goldAbstract readLetter
In one paragraph

Article in Blood cancer journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 12 institutions in 1 country.

Diana Al-SarayfiDepartment of Hematology, University Medical Center Groningen, Groningen, The Netherlands.ORCID 0000-0003-0496-6403
Frederik O MeeuwesDepartment of Hematology, Treant Hospital, Emmen, The Netherlands.
Müjde DurmazDepartment of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.ORCID 0000-0002-5724-1484
Djamila E IssaDepartment of Internal Medicine, Jeroen Bosch Hospital, 's-Hertogenbosch, Netherlands.
Rolf E BrouwerDepartment of Internal Medicine, Reinier de Graaf Gasthuis, Delft, The Netherlands.
Aart BeekerDepartment of Oncology, Spaarne Gasthuis, Hoofddorp, The Netherlands.
Anna van RhenenDepartment of Hematology, Cancer Center, UMC Utrecht, Utrecht, The Netherlands.
Pim G N J MutsaersDepartment of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Lara H BöhmerDepartment of Hematology, Haga Teaching Hospital, The Hague, The Netherlands.
Marjolein W M van der PoelDepartment of Internal Medicine, Division of Hematology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands.
Liane Te BoomeDepartment of Hematology, Haaglanden Medical Center, The Hague, The Netherlands.
Tom van MeertenDepartment of Hematology, University Medical Center Groningen, Groningen, The Netherlands.ORCID 0000-0002-5581-6950
Martine E D ChamuleauDepartment of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0002-0123-9182
Josée M ZijlstraDepartment of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Mirian BrinkDepartment of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.ORCID 0000-0002-6014-4810
Marcel NijlandDepartment of Hematology, University Medical Center Groningen, Groningen, The Netherlands. m.nijland@umcg.nl.
University Medical Center Groningen · NLNetherlands Comprehensive Cancer Organisation · NLVrije Universiteit Amsterdam · NLErasmus MC Cancer Institute · NLHaga Hospital · NLJeroen Bosch Ziekenhuis · NLMaastricht University · NLMedisch Centrum Haaglanden · NLReinier de Graaf Hospital · NLSpaarne Ziekenhuis · NLTreant Zorggroep · NLUniversity Medical Center Utrecht · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AnthracyclinesLymphoma, Large B-Cell, DiffuseAntineoplastic Combined Chemotherapy ProtocolsCyclophosphamideHumansPrednisoneTreatment OutcomeVincristineAnthracyclinesCyclophosphamidePrednisoneVincristine

Identifiers

PMID36055987
PMCPMC9440142
OpenAlexW4294176142

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.